EMBO Molecular Medicine (Feb 2013)

Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay

  • Loredana Fiorentino,
  • Michele Cavalera,
  • Stefano Menini,
  • Valentina Marchetti,
  • Maria Mavilio,
  • Marta Fabrizi,
  • Francesca Conserva,
  • Viviana Casagrande,
  • Rossella Menghini,
  • Paola Pontrelli,
  • Ivan Arisi,
  • Mara D'Onofrio,
  • Davide Lauro,
  • Rama Khokha,
  • Domenico Accili,
  • Giuseppe Pugliese,
  • Loreto Gesualdo,
  • Renato Lauro,
  • Massimo Federici

DOI
https://doi.org/10.1002/emmm.201201475
Journal volume & issue
Vol. 5, no. 3
pp. 441 – 455

Abstract

Read online

Abstract ADAM17 and its inhibitor TIMP3 are involved in nephropathy, but their role in diabetic kidney disease (DKD) is unclear. Diabetic Timp3−/− mice showed increased albuminuria, increased membrane thickness and mesangial expansion. Microarray profiling uncovered a significant reduction of Foxo1 expression in diabetic Timp3−/− mice compared to WT, along with FoxO1 target genes involved in autophagy, while STAT1, a repressor of FoxO1 transcription, was increased. Re‐expression of Timp3 in Timp3−/− mesangial cells rescued the expression of Foxo1 and its targets, and decreased STAT1 expression to control levels; abolishing STAT1 expression led to a rescue of FoxO1, evoking a role of STAT1 in linking Timp3 deficiency to FoxO1. Studies on kidney biopsies from patients with diabetic nephropathy confirmed a significant reduction in TIMP3, FoxO1 and FoxO1 target genes involved in autophagy compared to controls, while STAT1 expression was strongly increased. Our study suggests that loss of TIMP3 is a hallmark of DKD in human and mouse models and designates TIMP3 as a new possible therapeutic target for diabetic nephropathy.

Keywords